Drug discovery and optimization based on the co-crystal structure of natural product with target

被引:7
|
作者
Chen, Xing [1 ,3 ]
Varghese, Swapna [2 ]
Zhang, Zhaoyan [1 ]
Du, Juncheng [1 ]
Ruan, Banfeng [4 ]
Baell, Jonathan B. [2 ]
Liu, Xinhua [1 ]
机构
[1] Anhui Med Univ, Sch Pharm, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei 230032, Peoples R China
[2] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Melbourne, Vic 3052, Australia
[3] Anhui Med Univ, Sch Publ Hlth, Key Lab Populat Hlth Life Cycle, Hefei 230032, Peoples R China
[4] Hefei Univ, Key Lab Biofabricat Anhui Higher Educ, Hefei 230601, Peoples R China
基金
中国博士后科学基金;
关键词
BISTRAMIDE-A; CELL-CYCLE; PROTEIN PHOSPHATASE-1; RAPAMYCIN AY-22,989; IN-VITRO; INHIBITION; COMPLEX; PACTAMYCIN; POTENT; GELDANAMYCIN;
D O I
10.1016/j.ejmech.2024.116126
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Due to their structural diversities and prevalent biological activities, natural products (NPs) are momentous resources for drug discovery. Although NPs have a wide range of biological activities, many exhibit structural complexity that leads to synthetic difficulties, which combines with inefficient biological activity, toxicity, and unfavorable pharmacokinetic characteristics and ultimately imparts poor safety and efficacy outcomes. Progress in crystallization and computational techniques allow crystallography to have a seasonable influences on drug discovery. By co -crystallizing with proteins, therapeutic targets of NPs in specific diseases can be identified. By analyzing the co -crystal information, the structure -activity relationships (SARs) of NPs targeting specific proteins can be grasped. Under the guidance of co -crystal information, directional structural modification and simplification are powerful strategies for overcoming limitations of NPs, improving the success rate of NP -based drug discovery, and obtaining NP -based drugs with high selectivity, low toxicity and favorable pharmacokinetic characteristics. Here, we review the cocrystal information of a selection of NPs, focusing on the SARs of NPs reflected by co -crystal information and the modification and simplification strategies of NPs, and discuss how to apply co -crystal information in the optimization of NP -based lead compound.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™)
    Chackalamannil, Samuel
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (10) : 1623 - 1636
  • [22] Co-crystal formation based on structural matching
    Zhou, Liping
    Dodd, Stephanie
    Capacci-Daniel, Christina
    Garad, Sudhakar
    Panicucci, Riccardo
    Sethuraman, Vijay
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 88 : 191 - 201
  • [23] Keynote Lecture "Cheminformatics in natural product-based drug discovery"
    Chen, Y.
    Kirchmair, J.
    PLANTA MEDICA, 2022, 88 (15) : 1401 - 1401
  • [24] Recent developments in natural product-based drug discovery for tuberculosis
    Dong, Maryline
    Pfeiffer, Bernhard
    Altmann, Karl-Heinz
    DRUG DISCOVERY TODAY, 2017, 22 (03) : 585 - 591
  • [25] The host guest co-crystal approach to supramolecular structure
    Kane, JJ
    Nguyen, T
    Xiao, J
    Fowler, FW
    Lauher, JW
    MOLECULAR CRYSTALS AND LIQUID CRYSTALS, 2001, 356 : 449 - 458
  • [26] The structure of the melamine-cyanuric acid co-crystal
    Prior, Timothy J.
    Armstrong, Jennifer A.
    Benoit, David M.
    Marshall, Kayleigh L.
    CRYSTENGCOMM, 2013, 15 (29): : 5838 - 5843
  • [27] Structure and properties of a co-crystal of malonic acid with acetamide
    A. Yu. Tsyplenkova
    O. V. Kol’tsova
    N. N. Lobanov
    M. A. Ershov
    Yu. Yu. Pyl’chikova
    Journal of Structural Chemistry, 2016, 57 : 1691 - 1693
  • [28] STRUCTURE AND PROPERTIES OF A CO-CRYSTAL OF MALONIC ACID WITH ACETAMIDE
    Tsyplenkova, A. Yu.
    Kol'tsova, O. V.
    Lobanov, N. N.
    Ershov, M. A.
    Pyl'chikova, Yu. Yu.
    JOURNAL OF STRUCTURAL CHEMISTRY, 2016, 57 (08) : 1691 - 1693
  • [29] Artificial intelligence for natural product drug discovery
    Michael W. Mullowney
    Katherine R. Duncan
    Somayah S. Elsayed
    Neha Garg
    Justin J. J. van der Hooft
    Nathaniel I. Martin
    David Meijer
    Barbara R. Terlouw
    Friederike Biermann
    Kai Blin
    Janani Durairaj
    Marina Gorostiola González
    Eric J. N. Helfrich
    Florian Huber
    Stefan Leopold-Messer
    Kohulan Rajan
    Tristan de Rond
    Jeffrey A. van Santen
    Maria Sorokina
    Marcy J. Balunas
    Mehdi A. Beniddir
    Doris A. van Bergeijk
    Laura M. Carroll
    Chase M. Clark
    Djork-Arné Clevert
    Chris A. Dejong
    Chao Du
    Scarlet Ferrinho
    Francesca Grisoni
    Albert Hofstetter
    Willem Jespers
    Olga V. Kalinina
    Satria A. Kautsar
    Hyunwoo Kim
    Tiago F. Leao
    Joleen Masschelein
    Evan R. Rees
    Raphael Reher
    Daniel Reker
    Philippe Schwaller
    Marwin Segler
    Michael A. Skinnider
    Allison S. Walker
    Egon L. Willighagen
    Barbara Zdrazil
    Nadine Ziemert
    Rebecca J. M. Goss
    Pierre Guyomard
    Andrea Volkamer
    William H. Gerwick
    Nature Reviews Drug Discovery, 2023, 22 : 895 - 916
  • [30] Natural product drug discovery in the next millennium
    Cragg, GM
    Newman, DJ
    PHARMACEUTICAL BIOLOGY, 2001, 39 : 8 - 17